INS and metabolic dysfunction-associated steatohepatitis: On the other hand, sulfonylureas act on hepatic glucose metabolism through the stimulation of insulin secretion (Fig. 1) and treatment with sulfonylureas is associated with presence of significant fibrosis (OR 2.04, p = 0.022) but not NASH [11].